Search results for "lymphoma."

showing 10 items of 697 documents

Immunophenotypic profile and role of adhesion molecules in splenic marginal zone lymphoma with bone marrow involvement

2005

Abstract Splenic Marginal Zone Lymphoma (SMZL), with or without villous lymphocytes (VL+/-), is a low-grade lymphoproliferative disorder with constant involvement of the bone marrow (BM). Different BM infiltration patterns, mainly intra-sinusoidal, interstitial and nodular, have been described. Adhesion molecules (AMs) constitute a heterogeneous group of antigenic receptors playing a major role in leukocyte recruitment, in lymphocyte homing and in cellular-mediated immune response. Evolution and pattern of the BM infiltrate could be influenced by a variable expression of AM on SMZL lymphocytes. The degree and pattern of BM infiltration and the immunohistochemical expression of AM (H-CAM, BL…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyLymphomasplenic marginal zone lymphomaBiologyImmunophenotypingAntigenAntigens NeoplasmBone MarrowmedicineHumansLymphocytesSplenic marginal zone lymphomabone marrow involvementLymphocyte homing receptorAgedCell adhesion moleculeSplenic NeoplasmsHematologyMiddle Agedrole of adhesion moleculemedicine.diseaseImmunophenotypic profilemedicine.anatomical_structureOncologyReticular connective tissueImmunohistochemistryFemaleBone marrowCell Adhesion MoleculesInfiltration (medical)
researchProduct

Short telomeres in aggressive non-Hodgkin's lymphoma as a risk factor in lymphomagenesis

2007

Objective Telomeres cap chromosomal ends and help to maintain chromosomal integrity. Telomere shortening may result in chromosomal instability and, ultimately, malignant transformation of cells. It has not been systematically studied whether patients with malignancy have shortened telomeres in their normal, nontransformed cells, which might point to a preexisting disposition for chromosomal instability. Methods We designed an (age-) matched pair analysis that compared telomere length in nonmalignant peripheral leukocytes from previously untreated patients who recently developed an aggressive non-Hodgkin's lymphoma, with leukocytes from healthy individuals. Results Telomere lengths in B and …

AdultMaleCancer ResearchTelomeraseT-LymphocytesBiologyMalignancyMalignant transformationRisk FactorsChromosome instabilityGeneticsmedicineChromosomes HumanHumansRisk factorMolecular BiologyB-LymphocytesLymphoma Non-HodgkinCell BiologyHematologyTelomeremedicine.diseaseLymphomaNon-Hodgkin's lymphomaTelomereOxidative StressCell Transformation NeoplasticImmunologyFemaleGranulocytesExperimental Hematology
researchProduct

Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century.

2012

This study provides up-to-date and detailed cancer survival estimates of German patients with non-Hodgkin lymphoma (NHL, International Statistical Classification of Diseases 10th Revision [ICD-10] codes C82-C85) based on data from 11 cancer registries. Period analysis was used to calculate 5-year relative survival in 2002-2006, overall and by gender, age and histology. Comparison was made with patients with NHL in the United States (US) Surveillance, Epidemiology and End Results database in the same time period. Overall 5-year relative survival for patients with NHL in Germany in 2002-2006 was 62.8% and in the US was 65.1%. Survival decreased with age from 81.7% at age 15-49 to 46.5% at age…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentFollicular lymphomaHistory 21st CenturyYoung AdultOlder patientshemic and lymphatic diseasesInternal medicineGermanyEpidemiologymedicineHumansRegistriesAgedAged 80 and overRelative survivalbusiness.industryLymphoma Non-HodgkinCancerHematologyHistory 20th CenturyMiddle Agedmedicine.diseaseUnited StatesLymphomaOncologyImmunologyPeriod AnalysisHodgkin lymphomaFemalebusinessSEER ProgramLeukemialymphoma
researchProduct

The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry.

2014

Our specialized population-based registry has allowed us to explore changes in incidence and survival by subtype over the last 30 years. Between 1980 and 2009, 4790 cases of lymphoid malignancies were registered using the International Classification of Diseases for Oncology. The incidence rate of lymphoid malignancies was 20.5 per 100,000 inhabitants per year, and ranged from 0.1 to 4 according to subtype. Five-year net survival was 65%, and ranged from 41% to 93% according to subtype. We observed an increase in 5-year net survival between the periods 1980-1989 and 2000-2009 (58% vs. 70%). This was observed in most but not all subtypes. Our long-standing population-based registry allowed u…

AdultMaleCancer Researchmedicine.medical_specialtyAdolescentLymphomaPopulationYoung AdultSurvival probabilityInternal medicinemedicineHumansRegistrieseducationChildNet SurvivalAgedAged 80 and overeducation.field_of_studyLeukemiabusiness.industryIncidence (epidemiology)IncidenceHematologyMiddle AgedSurvival AnalysisCancer registryOncologyLymphoid malignancyChild PreschoolHematologic NeoplasmsPopulation SurveillanceImmunologyFemaleFrancebusinessPopulation-Based RegistryInternational Classification of Diseases for OncologyFollow-Up StudiesLeukemialymphoma
researchProduct

Atopic disease and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis

2009

AbstractWe performed a pooled analysis of data on atopic disease and risk of non–Hodgkin lymphoma (NHL) from 13 case-control studies, including 13,535 NHL cases and 16,388 controls. Self-reported atopic diseases diagnosed 2 years or more before NHL diagnosis (cases) or interview (controls) were analyzed. Pooled odds ratios (OR) and 95% confidence intervals (95% CI) were computed in two-stage random-effects or joint fixed-effects models, and adjusted for age, sex, and study center. When modeled individually, lifetime history of asthma, hay fever, specific allergy (excluding hay fever, asthma, and eczema), and food allergy were associated with a significant reduction in NHL risk, and there wa…

AdultMaleCancer Researchmedicine.medical_specialtyAllergyAdolescentCutaneous lymphomaArticleAtopyYoung AdultMeta-Analysis as Topicimmune system diseasesRisk FactorsInternal medicinehemic and lymphatic diseasesmedicineHypersensitivityHumansRisk factorAsthmaAgedAged 80 and overbusiness.industryLymphoma Non-HodgkinOdds ratioMiddle Agedmedicine.diseaseNon-Hodgkin's lymphomaOncologyCase-Control StudiesImmunologyHay feverFemalebusiness
researchProduct

A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas

2010

The clinical course of peripheral T-cell lymphoma (PTCL) is usually aggressive and the prognosis unfavorable. Therefore, there is a need for improvement of treatment options. Patients with newly diagnosed (n = 27) or refractory/relapsed (n = 11) PTCL received a combination of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin. The overall response rate (ORR) was 61%, with a complete response rate of 39%. In newly diagnosed patients the ORR was 63%, the median overall survival 25.9 months, and progression-free survival 11.8 months. In relapsed/refractory patients the median OS was 6.1 months. The most frequent grade 3/4 toxicities were leukopenia (95% of patients) and thrombocytopen…

AdultMaleCancer Researchmedicine.medical_specialtyCyclophosphamideAntibodies Neoplasmmedicine.medical_treatmentPhases of clinical researchAntibodies Monoclonal HumanizedLymphoma T-CellGastroenterologyDisease-Free SurvivalRefractoryRecurrenceInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAlemtuzumabCyclophosphamideAgedChemotherapyLeukopeniabusiness.industryAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseLymphomaFludarabineSurgeryTreatment OutcomeOncologyDoxorubicinAlemtuzumabFemalemedicine.symptombusinessVidarabinemedicine.drugLeukemia & Lymphoma
researchProduct

Non-Hodgkin lymphoma and obesity: A pooled analysis from the InterLymph consortium

2008

Nutritional status is known to alter immune function, a suspected risk factor for non-Hodgkin lymphoma (NHL). To investigate whether long-term over, or under, nutrition is associated with NHL, self-reported anthropometric data on weight and height from over 10,000 cases of NHL and 16,000 controls were pooled across 18 case-control studies identified through the International Lymphoma Epidemiology Consortium. Study-specific odds ratios (OR) were estimated using logistic regression and combined using a random-effects model. Severe obesity, defined as BMI of 40 kg m-2 or more, was not associated with NHL overall (pooled OR = 1.00, 95% confidence interval (CI) 0.70-1.41) or the majority of NHL …

AdultMaleCancer Researchmedicine.medical_specialtyInternational CooperationOverweightRisk AssessmentArticleBody Mass IndexRisk FactorsInternal medicinehemic and lymphatic diseasesEpidemiologyOdds RatiomedicineHumansObesityRisk factorAgedbusiness.industryLymphoma Non-HodgkinBody WeightNon-Hodgkin lymphoma obesity pooled analysis InterLymph consortiumOdds ratioMiddle Agedmedicine.diseaseObesityBody HeightConfidence intervalSurgeryOncologyFemaleLymphoma Large B-Cell Diffusemedicine.symptomUnderweightbusinessBody mass index
researchProduct

Splenic marginal zone lymphoma with or without villous lymphocytes

2004

BACKGROUND Splenic marginal zone lymphoma (SMZL) is a well defined pathologic entity. However, questions regarding the bone marrow infiltration rate, the minimal diagnostic data set, and therapy remain unanswered. METHODS Clinical-pathologic features and outcomes of 57 consecutive patients who had splenomegaly with no clinically significant lymphadenomegaly and who were diagnosed with SMZL with or without (±) villous lymphocytes (VL) were reviewed. RESULTS SMVL ± VL occurred mostly in elderly males (median age, 62 years ± 10 years; male-to-female ratio, (1.85). Anemia was recorded in 49% of patients, and 30% of patients had moderate thrombocytopenia. Leukocytosis and leukopenia were found i…

AdultMaleCancer Researchmedicine.medical_specialtyLymphomaAnemiamedicine.medical_treatmentSplenectomysplenic marginal zone lymphomaGastroenterologyBone marrow biopsyIntrasinusoidalInternal medicinemedicineHumansLymphocytesLeukocytosisSplenic marginal zone lymphomaSurvival rateAgedAged 80 and overLeukopeniabusiness.industrySplenic Neoplasmssplenic marginal zone lymphoma; PrognosisSplenic lymphoma with villous lymphocytesMiddle AgedPrognosismedicine.diseaseSplenic NeoplasmSurgerySurvival Ratemedicine.anatomical_structureOncologySplenectomySplenic lymphoma with villous lymphocyteLymphocyteFemaleBone marrowmedicine.symptombusinessHumanCancer
researchProduct

Cytogenetic findings in secondary acute nonlymphocytic leukemia

1992

Abstract We here report the results of cytogenetic studies carried out in eight patients with acute nonlymphocytic leukemia developed after primary neoplasias. In seven of the reported cases, clonal chromosome aberrations were found, some being specific of de novo acute nonlymphocytic leukemia (ANLL). Numerical abnormalities were detected, such as the total monosomy of chromosomes 5, 7, 21, trisomy of chromosomes 8, 11, 15, and duplication of chromosome Y. Structural changes were also observed: a del(12)(p12), a del(16)(q22), the translocations t(3;5)(p21;q35),t(3;7)(p21;q35), and t(12;14)(p12;q32) and other changes involving chromosome 8. The finding of a hypertetraploid karyotype with com…

AdultMaleCancer Researchmedicine.medical_specialtyMonosomyChromosomal translocationBiologyTranslocation GeneticPolyploidyMonosomyhemic and lymphatic diseasesGeneticsmedicineHumansMolecular BiologyAgedChromosome AberrationsCytogeneticsChromosomeNeoplasms Second PrimaryKaryotypeMiddle Agedmedicine.diseaseLymphomaLeukemia Myeloid AcuteLeukemiaImmunologyCancer researchChromosomes Human Pair 5FemaleTrisomyChromosomes Human Pair 7Cancer Genetics and Cytogenetics
researchProduct

Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.

2016

Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group

AdultMaleCancer Researchmedicine.medical_specialtyMyeloidAdolescentmedicine.disease_causeCohort Studies03 medical and health sciencesYoung Adult0302 clinical medicinehemic and lymphatic diseasesInternal medicineCEBPAmedicineHumansneoplasmsAgedMutationHematologybusiness.industryMyeloid leukemiaHematologyMiddle Agedmedicine.diseaseLymphomaGATA2 Transcription FactorHaematopoiesisLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureOncology030220 oncology & carcinogenesisMutationCancer researchCCAAT-Enhancer-Binding ProteinsFemalebusiness030215 immunologyLeukemia
researchProduct